Search Results

Comparison of dual nucleoside-analogue reverse-transcriptase inhibitor regimens with and without nelfinavir in children with HIV-1 who have not previously been treated: the PENTA 5 randomised trial.

Subjects: NUCLEOSIDES; REVERSE transcriptase; MEDICAL care of HIV-positive persons

• Source: Lancet. 3/2/2002, Vol. 359 Issue 9308, p733. 8p. 1 Diagram, 6 Charts, 1 Graph.

Record details

Mitochondrial toxicity induced by nucleoside-analogue reverse-transcriptase inhibitors is a key factor in the pathogenesis of antiretroviral-therapy-related lipodystrophy.

• Authors : Brinkman, Kees; Smeitink, Jan A.; Romijn, Johannes A.

Subjects: NUCLEOSIDES; WHIPPLE'S disease; OBESITY

• Source: Lancet. 9/25/1999, Vol. 354 Issue 9184, p1112-1115. 4p. 3 Diagrams.

Record details

Fatal portal hypertension, liver failure, and mitochondrial dysfunction after HIV-1 nucleoside analogue-induced hepatitis and lactic acidaemia.

• Authors : Carr, Andrew; Morey, Adrienne; Mallon, Patrick

Subjects: NUCLEOSIDES; HIV-positive persons; PORTAL hypertension

• Source: Lancet. 5/5/2001, Vol. 357 Issue 9266, p1412-1414. 3p. 1 Black and White Photograph.

Record details

HIV nucleoside analogues: new adverse effects on mitochondria?

• Authors : Morris, Andrew A. M.; Carr, Andrew; Morris, A A¹ (AUTHOR)

Subjects: *MATERNAL-fetal exchange; *NUCLEOSIDES; *HIV infection transmission

• Source: Lancet. 9/25/1999, Vol. 354 Issue 9184, p1046-1047. 2p.

Record details

Relevance of AIDS treatment with two nucleoside analogues alone.

• Authors : Weidle, P.J.; Mbidde, E.; Djomand, G.

Subjects: *AIDS treatment; *NUCLEOSIDES; *AZIDOTHYMIDINE

• Source: Lancet. 6/12/1999, Vol. 353 Issue 9169, p1989-1990. 2p.

Record details

Risk of myocardial infarction and nucleoside analogues.

• Authors : Stein, James H.¹ ; Currier, Judith S.²

Subjects: NUCLEOSIDES; REVERSE transcriptase; MYOCARDIAL infarction risk factors

• Source: Lancet. 4/26/2008, Vol. 371 Issue 9622, p1391-1392. 2p. 1 Color Photograph.

Record details

Efavirenz: effective against HIV-1, but who can afford to benefit?

• Authors : Ahmad, Khabir

Subjects: NUCLEOSIDES; AIDS treatment; NUCLEOTIDES

• Source: Lancet. 1/1/2000, Vol. 355 Issue 9197, p46-46. 2/5p. 1 Color Photograph.

Record details

3-Deaza-adenosine and inhibition of HIV.

• Authors : FLEXNER, CHARLES W.; HILDRETH, JAMES E.; KUNCL, RALPH W.

Subjects: NUCLEOSIDES; HIV prevention; PHOSPHOLIPIDS

• Source: Lancet. 2/15/1992, Vol. 339 Issue 8790, p438-438. 1p. 1 Graph.

Record details

Association between presence of HLA-B*5701, HLA-DR7, and HLA-DQ3 and hypersensitivity to HIV-1 reverse-transcriptase inhibitor abacavir.

• Authors : Mallal, S; Nolan, D; Witt, C

Subjects: MAJOR histocompatibility complex genetics; MEDICAL care of HIV-positive persons; NUCLEOSIDES

• Source: Lancet. 3/2/2002, Vol. 359 Issue 9308, p727-732. 6p. 2 Diagrams, 3 Charts.

Record details

Virological and immunological outcomes at 3 years after starting antiretroviral therapy with regimens containing non-nucleoside reverse transcriptase inhibitor, protease inhibitor, or both in INITIO: open-label randomised trial.

• Authors : Babiker, Abdel G.

Subjects: ANTIRETROVIRAL agents; ANTIVIRAL agents; HIV infections

• Source: Lancet. 7/22/2006, Vol. 368 Issue 9532, p287-298. 12p.

Record details